Table 3.
Change in red blood cell fatty acid levels (mol%), comparing the Omega 3-6 group to the placebo group, after 90 days of supplementation, Omega Heroes Trial (Ohio, USA)
| Fatty Acid | Baseline (mean (SD), mol%) |
End of Trial (mean (SD), mol%) |
Pre-Post Change (Omega 3-6 - Placebo) (mol%, 95% CI, p-value)a |
||
|---|---|---|---|---|---|
| Omega 3-6 n=36b |
Placebo n=33 |
Omega 3-6 n=29 |
Placebo n=30 | ||
| C12:0 | 0.81 (0.14) | 0.80 (0.11) | 0.80 (0.08) | 0.81 (0.17) | −0.02 (−0.09, 0.06); p=0.65 |
| C14:0 | 1.07 (0.26) | 1.05 (0.22) | 1.09 (0.31) | 1.05 (0.21) | 0.04 (−0.10, 0.18); p=0.59 |
| C16:0 | 24.71 (1.26) | 24.60 (1.46) | 25.01 (2.13) | 24.52 (2.57) | 0.35 (−0.87, 1.56); p=0.57 |
| C16:1 | 0.98 (0.20) | 1.03 (0.21) | 0.98 (0.16) | 0.95 (0.13) | 0.04 (−0.03, 0.11); p=0.29 |
| C18:0 | 14.44 (1.13) | 14.79 (1.12) | 14.44 (1.21) | 15.06 (1.48) | −0.56 (−1.27, 0.16); p=0.12 |
| C18:1n9c | 17.41 (1.74) | 17.51 (1.62) | 16.62 (2.07) | 17.65 (2.59) | −0.92, −1.99, 0.15); p=0.09 |
| C18:2 | 19.74 (2.66) | 19.68 (2.34) | 18.73 (2.24) | 19.45 (2.24) | −0.63 (−1.78, 0.52); p=0.28 |
| C20:0 | 0.67 (0.08) | 0.68 (0.12) | 0.67 (0.07) | 0.68 (0.08) | −0.01 (−0.05, 0.03); p=0.71 |
| C18:3n6 | 0.59 (0.10) | 0.60 (0.09) | 0.59 (0.07) | 0.70 (0.63) | −0.11 (−0.35, 0.13); p=0.37 |
| C18:3n3 | 0.83 (0.17) | 0.82 (0.15) | 0.78 (0.12) | 0.88 (0.13) | −0.11 (−0.17, −0.04); p=0.002 |
| C20:4 | 15.39 (1.66) | 15.31 (1.72) | 13.72 (2.37) | 14.98 (1.75) | −1.29 (−2.27, −0.310; p=0.01 |
| C20:5 | 0.79 (0.19) | 0.80 (0.27) | 2.30 (1.86) | 0.80 (0.33) | 1.43 (0.77, 2.09); p<.0001 |
| C22:6n3 | 2.57 (0.70) | 2.33 (0.37) | 4.26 (1.53) | 2.46 (0.92) | 1.52 (0.89, 2.15); p<.0001 |
a
Model-based estimates.
b
One child in the Omega 3-6 group was missing data at baseline.